| symbol | LINC00673 |
| name | long intergenic non-protein coding RNA 673 |
| location | 17q24.3 |
| alias_symbol | HI-LNC75|SLNCR1 |
| alias_name | Human Islet Long Non Coding RNA 75 |
| Tissue | lung,others,pancreas, |
| Cancer | melanoma,non-small-cell lung cancer,pancreatic cancer, |
LINC00673 expression is up-regulated in non-small cell lung cancer (NSCLC) tissues and associated with larger tumors, lymph node metastasis, more advanced tumors and prognosis. LINC00673 is localized in both the nucleus and cytosol. LINC00673 promotes NSCLC cell proliferation through regulating CDK6 expression. Moreover, LINC00673 silences NCALD transcription by binding with Histone demethylase lysine specific demethylase 1 (LSD1) (1).
In melanoma, LINC00673 is also up-regulated and associated with survival outcome. It can increase melanoma invasion. Further studies find that AR and Brn3a bind to adjacent LINC00673 sequence. The AR and Brn3a binding sites are required for LINC00673-induced up-regulation of the MMP9 promoter (2).
While in pancreatic cancer, LINC00673 is a potential tumor suppressor whose germline variation is associated with pancreatic cancer risk. LINC00673 is able to reinforce the interaction between PTPN11 and PRPF19 (an E3 ubiquitin ligase), thus promoting PTPN11 degradation through ubiquitination, which causes the diminished SRC-ERK oncogenic signaling and the enhanced activation of the STAT1-dependent antitumor response. A G>A change at rs11655237 in exon 4 of LINC00673 creates a target site for miR-1231 binding, which could diminish the effect of LINC00673 in an allele-specific manner and thus confer susceptibility to tumorigenesis (3).
| LncRNA | tissue | cancer type | expression level | oncogene/suppress gene | pathway | binding gene/factor | associated gene/factor | proliferation | apoptosis | migration | EMT | invasion | metastasis | prognosis | tag | PMID | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 | LINC00673 | lung | non-small-cell lung cancer | up | onco | LSD1 | CDK6+,NCALD- | + | - | 27027352 | |||||||
| 1 | LINC00673 | others | melanoma | up | onco | AR,Brn3a | MMP9+ | + | - | 27210747 | |||||||
| 2 | LINC00673 | pancreas | pancreatic cancer | / | TS | miR-1231 | PTPN11 | SNP | 27213290 |
| entrez_id | 100499467 |
| ucsc_id | |
| Ensembl_gene_id | |
| HGNC_id | HGNC:44354 |
| Omim_id | 617079 |
| cosmic | |
| lncrnadb |
[1]. Shi X, Ma C, Zhu Q, Yuan D, Sun M, et al. (2016). Upregulation of long intergenic noncoding RNA 00673 promotes tumor proliferation via LSD1 interaction and repression of NCALD in non-small-cell lung cancer. Oncotarget 7(18): 25558-75. link pubmed
[2]. Schmidt K, Joyce CE, Buquicchio F, Brown A, Ritz J, et al. (2016). The lncRNA SLNCR1 Mediates Melanoma Invasion through a Conserved SRA1-like Region. Cell Rep 15(9): 2025-37. link pubmed
[3]. Zheng J, Huang X, Tan W, Yu D, Du Z, et al. (2016). Pancreatic cancer risk variant in LINC00673 creates a miR-1231 binding site and interferes with PTPN11 degradation. Nat Genet 48(7): 747-57. link pubmed